Monte Rosa Therapeutics, Inc.

BOSTON, MA · Founded 2019 · CIK 0001826457 · Biotech · Public

Drug discovery platform that promotes targeted protein ubiquitination and proteasomal degradation for therapeutic protein knockdown

monterosatx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$143M
2 Form D · Mar 2021
67 months since last filing
Contracts
—
No federal contracts on record
Patents
37
1 granted · 36 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$48,000,000
Private capital raisedForm D · SEC$94,999,984
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1265Mediar Therapeutics—$75M
1266MOLECULAR TECHNOLOGIES LABORATORIES LLC——
1267MARTINGALE LABS, INC.——
1268Monte Rosa Therapeutics, Inc.—$143M
1269Tyra Biosciences, Inc.—$200M
1270NEUROEPIGENIX, LLC——
1271Third Harmonic Bio——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 9 related persons
  • Ali BehbahaniDirector
  • Kim BlackwellDirector
  • Bradley BolzonDirector
  • Chandra LeoDirector
  • Alexander MaywegDirector
  • Drew SchiffDirector
  • Christine SiuDirector
  • Ajim TamboliExecutive Officer
  • Markus WarmuthDirector · Executive Officer

Patents

USPTO · 1 granted of 37
  • COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORSapplication
  • Isoindolinone Compoundsgranted
  • Methods Of Desiging Molecular Glue Degradersapplication
  • Targeted Protein Degradationapplication
  • Methods Of Preparing Compoundsapplication
  • Combination Therapy Comprising GSPT1-DIRECTED Molecular Glue Degraders And PI3K/AKT/MTOR Pathway Inhibitorsapplication
  • Molecular Glue Degraders And Methods Of Using The Sameapplication
  • Molecular Glue Degraders And Methods Of Using The Sameapplication
  • Molecular Glue Degraders And Methods Of Using The Sameapplication
  • Programmable E3 Ligase Identificationapplication
  • Targeted Degradation Of VAV1application
  • Ternary Complex Modelling For Molecular Gluesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.